Breakthrough T1D Celebrates Approval of Tzield for Use in Young Children to Delay the Onset of Insulin-Dependent Type 1 Diabetes

NEW YORK, April 22, 2026 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and Drug Administration (FDA) to approve Sanofi's Tzield (teplizumab-mzwv) for use in children...